Statistical clustering of documents via stochastic blockmodels.

J Appl Stat

Department of Statistics, Western Michigan University, Kalamazoo, MI, USA.

Published: September 2023

As the online market grows rapidly, people are relying more on product review when they purchase the product. Hence, many companies and researchers are interested in analyzing product review which essentially a text data. In the current literature, it is common to use only text analysis tools to analyze text dataset. But in our work, we propose a method that utilizes both text analysis method such as topic modeling and statistical network model to build network among individuals and find interesting communities. We introduce a promising framework that incorporates topic modeling technique to define the edges among the individuals and form a network and uses stochastic blockmodels (SBM) to find the communities. The power of our proposed method is demonstrated in real-world application to Amazon product review dataset.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271127PMC
http://dx.doi.org/10.1080/02664763.2023.2247617DOI Listing

Publication Analysis

Top Keywords

product review
12
stochastic blockmodels
8
text analysis
8
topic modeling
8
statistical clustering
4
clustering documents
4
documents stochastic
4
blockmodels online
4
online market
4
market grows
4

Similar Publications

Autograft composition and outcome-towards an optimal graft?

Cytotherapy

December 2024

Department of Medicine, Kuopio University Hospital, Kuopio, Finland. Electronic address:

The amount of CD34 cells has been for decades the most important marker of autologous graft quality, but other graft cells, including various lymphocyte subsets, have gained some interest. This review attempts to summarize what is known about autograft cellular composition regarding post-transplant outcomes. The amount of CD34 cells in the graft is associated with tempo of platelet recovery.

View Article and Find Full Text PDF

Cellular and gene therapy (CGT) products have emerged as a popular approach in regenerative medicine, showing promise in treating various pancreatic and liver diseases in numerous clinical trials. Before these therapies can be tested in human clinical trials, it is essential to evaluate their safety and efficacy in relevant animal models. Such preclinical testing is often required to obtain regulatory approval for investigational new drugs.

View Article and Find Full Text PDF

Background: Selective androgen receptor modulators (SARMs) are small-molecule compounds that exert agonist and antagonist effects on androgen receptors in a tissue-specific fashion. Because of their performance-enhancing implications, SARMs are increasingly abused by athletes. To date, SARMs have no Food and Drug Administration approved use, and recent case reports associate the use of SARMs with deleterious effects such as drug-induced liver injury, myocarditis, and tendon rupture.

View Article and Find Full Text PDF

Background: Bilateral risk-reducing mastectomies (RRMs) have been proven to decrease the risk of breast cancer in patients at high risk owing to family history or having pathogenic genetic mutations. However, few resources with consolidated data have detailed the patient experience following surgery. This systematic review features patient-reported outcomes for patients with no breast cancer history in the year after their bilateral RRM.

View Article and Find Full Text PDF

Selenium, an essential trace mineral for health, has seen a rise in clinical trials over the past nearly 5 decades. Our aim here is to provide a comprehensive and concise overview of selenium clinical trials from 1976 to 2023. Overall, the evolution of selenium clinical trials over 48 years has advanced through phases of emergence, prosperity, and either stability or transition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!